Adès L et al. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML. Blood Adv 2022;6(17):5132-45. Abstract
Bazinet A et al. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: Phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study. Lancet Haematol 2022;9(10):e756-65. Abstract
Bernard E et al. Molecular International Prognostic Scoring System for myelodysplastic syndromes. NEJM Evid 2022;1(7). Abstract
Cadenas FL et al. Evaluation of lenalidomide (LEN) vs placebo in non-transfusion dependent low risk del(5q) MDS patients. Final results of Sintra-REV phase III international multicenter clinical trial. ASH 2022;Abstract 460.
Carvajal LA et al. SYK inhibitors, entospletinib and lanraplenib, show potent anti-leukemic activity in combination with targeted agents. ASH 2022;Abstract 2639.
Cortes JE et al. Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: Post hoc analysis of a randomized, phase 3 trial. J Hematol Oncol 2022;15(1):155. Abstract
Cortes JE et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed/refractory mIDH1 acute myeloid leukemia. Results from a planned interim analysis of a phase 2 pivotal clinical trial. ASH 2022;Abstract 2757.
de Botton S et al. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: A randomized phase 3 trial. Blood 2023;141(2):156-67. Abstract
DiNardo CD et al. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol 2022;97(8):1035-43. Abstract
Erba H et al. Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML. EHA 2022;Abstract S100.
Erba HP et al. Update on a phase 1/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia. ASH 2022;Abstract 64.
Fenaux P et al. Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial. ASCO 2022;Abstract 7056.
Garcia-Manero G et al. ASTX727-03: Phase 1 study evaluating oral decitabine/cedazuridine (ASTX727) low-dose (LD) in lower-risk myelodysplastic syndromes (LR-MDS) patients. ASH 2022;Abstract 461.
Garelius H et al. Erythropoietin stimulation agents significantly improve outcome in lower risk MDS. EHA 2022;Abstract S168.
Geissler K et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized crossover phase 3 study of an oral hypomethylating agent DEC-C compared to IV decitabine in AML patients. EHA 2022;Abstract P573.
Issa GC et al. The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (pts) with KMT2A-rearranged or NPM1 mutant AML: Updated results of a phase (Ph) 1 study. ASH 2022;Abstract 63.
Levis MJ et al. QuANTUM-First trial: FLT3-ITD-specific MRD clearance is associated with improved overall survival. ASH 2022;Abstract 225.
Montesinos P et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med 2022;386(16):1519-31. Abstract
Perl AE et al. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 2022;139(23):3366-75. Abstract
Pratz KW et al. Long-term follow-up of the phase 3 VIALE-A clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. ASH 2022;Abstract 219.
Ravandi F et al. COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). ASCO 2022;Abstract TPS7064.
Sallman DA et al. Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 phase 1b study results. ASCO 2022;Abstract 7017.
Santini V et al. Disease characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in adult patients with higher-risk myelodysplastic syndromes (MDS) participating in two randomized, double-blind, placebo-controlled studies with intravenous sabatolimab added to hypomethylating agents (HMA) (STIMULUS-MDS1 and MDS2). ASH 2022;Abstract 559.
Savona MR et al. Prolonged survival in bi-allelic TP53-mutated (TP53mut) MDS subjects treated with oral decitabine/cedazuridine in the ASCERTAIN trial (ASTX727-02). ASH 2022;Abstract 854.
Short N et al. Updated results from a phase I/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia. ASH 2022;Abstract 831.
Uy GL et al. Lower-intensity CPX-351 + venetoclax for patients with newly diagnosed AML who are unfit for intensive chemotherapy. ASCO 2022;Abstract 7031.
Venugopal S et al. A phase I/II study of venetoclax in combination with ASTX727 (decitabine/cedazuridine) in treatment-naïve high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). EHA 2022;Abstract P784.
Wei AH et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood 2022;140(25):2754-6. Abstract
Zeidan AM et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol 2023;98(2):272-81. Abstract
Zeidan AM et al. Primary results of Stimulus-MDS1: A randomized, double-blind, placebo-controlled Phase II study of TIM-3 inhibition with sabatolimab added to hypomethylating agents (HMAs) in adult patients with higher-risk myelodysplastic syndromes (MDS). ASH 2022;Abstract 853.